Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies

Blood (2018) 132 (Supplement 1): 1882.

DOI: https://doi.org/10.1182/blood-2018-99-113169

Published: 2018

Journal Articles

Clinical and Molecular Characterization of Primary Plasma Cell Leukemia

Sandra Susanibar, MD, Pingping Qu, Antje Hoering, Sharmilan Thanendrarajan, MD, Jorge Jo Kamimoto, MD, Meera Mohan, MD, Pankaj Mathur, MD, Shadiqul Hoque, MD, Muthukumar Radhakrishnan, MD, Phil Farmer, Nathan Petty, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Faith E. Davies, MD, Daisy Alapat, MD, Barlogie Bart, Gareth J. Morgan, MD PhD, Carolina D. Schinke, MD

Blood (2017) 130 (Supplement 1): 3047.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3047.3047

Published: 2017

Journal Articles

High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1

Blood (2016) 128 (22): 4416.

DOI: https://doi.org/10.1182/blood.V128.22.4416.4416

Published: 2016

Journal Articles

A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments

Blood (2016) 128 (22): 117.

DOI: https://doi.org/10.1182/blood.V128.22.117.117

Published: 2016

Journal Articles

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Blood (2016) 128 (22): 2064.

DOI: https://doi.org/10.1182/blood.V128.22.2064.2064

Published: 2016

Journal Articles

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Blood (2015) 126 (23): 3181.

DOI: https://doi.org/10.1182/blood.V126.23.3181.3181

Published: 2015

Journal Articles

Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma

James E McDonald, Marcus M Kessler, Michael Gardner, Amy Buros, PhD, Sarah Waheed, MD, James Ntambi, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Christoph Heuck, MD, Nathan Petty, MS, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Alan Mitchell, Antje Hoering, Bart Barlogie, MD PhD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2015) 126 (23): 724.

DOI: https://doi.org/10.1182/blood.V126.23.724.724

Published: 2015

Journal Articles

Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma

Blood (2015) 126 (23): 2979.

DOI: https://doi.org/10.1182/blood.V126.23.2979.2979

Published: 2015

Journal Articles

Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Adam Rosenthal, Nathan Petty, MS, Maurizio Zangari, MD, Christoph Heuck, MD, Frits van Rhee, MD PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J Morgan, MDPhD, Faith E Davies, MD, Bart Barlogie, MD PhD

Blood (2015) 126 (23): 5395.

DOI: https://doi.org/10.1182/blood.V126.23.5395.5395

Published: 2015

Journal Articles

The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM

Blood (2015) 126 (23): 372.

DOI: https://doi.org/10.1182/blood.V126.23.372.372

Published: 2015

Journal Articles

Outcomes of Autologous Transplantation for Treatment-Related AML and MDS in Previously Treated Multiple Myeloma Patients (pts)

Shebli Atrash, Bart Barlogie, MD PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Sarah Waheed, MD, Clyde Bailey, Nathan Petty, MS, Christoph Heuck, MD, Gareth J Morgan, MDPhD, Yogesh Jethava, MD

Blood (2015) 126 (23): 1997.

DOI: https://doi.org/10.1182/blood.V126.23.1997.1997

Published: 2015

Journal Articles

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)

Madhav V. Dhodapkar, Rachael Sexton, Sarah Waheed, Saad Usmani, Xenofon Papanikolaou, Bijay Nair, Nathan Petty, John D. Shaughnessy, Jr, Antje Hoering, John Crowley, Robert Z. Orlowski, Bart Barlogie

Blood (2014) 123 (1): 78–85.

DOI: https://doi.org/10.1182/blood-2013-07-515239

Published: 2014

Includes: Supplemental data

Journal Articles

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Blood (2013) 121 (23): 4753–4757.

DOI: https://doi.org/10.1182/blood-2012-11-466961

Published: 2013

Includes: Supplemental data

Journal Articles

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3

Saad Z. Usmani, Alan Mitchell, Sarah Waheed, John Crowley, Antje Hoering, Nathan Petty, Tracy Brown, Twyla Bartel, Elias Anaissie, Frits van Rhee, Bart Barlogie

Blood (2013) 121 (10): 1819–1823.

DOI: https://doi.org/10.1182/blood-2012-08-451690

Published: 2013

Includes: Supplemental data

Journal Articles

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance

Saad Z. Usmani, Rachel Sexton, Antje Hoering, Christoph J. Heuck, Bijay Nair, Sarah Waheed, Yazan Al Sayed, Nabeel Chauhan, Nisar Ahmad, Shebli Atrash, Nathan Petty, Frits van Rhee, John Crowley, Bart Barlogie

Blood (2012) 120 (8): 1597–1600.

DOI: https://doi.org/10.1182/blood-2012-04-421883

Published: 2012

Journal Articles

Super (S)-Beam for Advanced and Refractory Multiple Myeloma (ARMM)

Sarah Waheed, MD, Bijay Nair, MD, MPH, Yazan Alsayed, MD, Monica Grazziutti, Elias J. Anaissie, MD, Frits van Rhee, MD, PhD, Nathan Petty, Doug Steward, Jackie Szymonifka, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 4800.

DOI: https://doi.org/10.1182/blood.V116.21.4800.4800

Published: 2010

Journal Articles

Autotransplants for Multiple Myeloma (MM) – An Update of the Arkansas Experience Since 1989 In Almost 4000 Patients with Special Emphasis on Third and Further Transplants.

Bijay Nair, MD, MPH, Elias J. Anaissie, MD, Sarah Waheed, MD, Yazan Alsayed, MD, Rachael Sexton, Nathan Petty, Frits van Rhee, MD, PhD, Antje Hoering, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 1352.

DOI: https://doi.org/10.1182/blood.V116.21.1352.1352

Published: 2010

Journal Articles

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components.

Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD, Jackie Szymonifka, Elias J. Anaissie, MD, Bijay Nair, MD, MPH, Sarah Waheed, MD, Yazan Alsayed, MD, Nathan Petty, John Shaughnessy, Jr, PhD, Antje Hoering, PhD, John Crowley, PhD

Blood (2010) 116 (21): 1356.

DOI: https://doi.org/10.1182/blood.V116.21.1356.1356

Published: 2010

Journal Articles

Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B

Elias J. Anaissie, MD, Frits van Rhee, MD, PhD, Antje Hoering, PhD, Sarah Waheed, MD, Yazan Alsayed, MD, Nathan Petty, Monica Grazziutti, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 368.

DOI: https://doi.org/10.1182/blood.V116.21.368.368

Published: 2010

Journal Articles

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

Frits van Rhee, Jackie Szymonifka, Elias Anaissie, Bijay Nair, Sarah Waheed, Yazan Alsayed, Nathan Petty, John D. Shaughnessy, Jr, Antje Hoering, John Crowley, Bart Barlogie

Blood (2010) 116 (8): 1220–1227.

DOI: https://doi.org/10.1182/blood-2010-01-264333

Published: 2010

NARROW

Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies

Clinical and Molecular Characterization of Primary Plasma Cell Leukemia

High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1

A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma

Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma

Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM

Outcomes of Autologous Transplantation for Treatment-Related AML and MDS in Previously Treated Multiple Myeloma Patients (pts)

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance

Super (S)-Beam for Advanced and Refractory Multiple Myeloma (ARMM)

Autotransplants for Multiple Myeloma (MM) – An Update of the Arkansas Experience Since 1989 In Almost 4000 Patients with Special Emphasis on Third and Further Transplants.

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components.

Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only